пятница, 19 августа 2016 г.

Valeant's battered stock gets short-lived bump from revised creditor deal

Valeant's battered stock gets short-lived bump from revised creditor deal


Valeant Pharmaceuticals International is getting a much-needed break from its lenders, but at the cost of higher interest rates and additional one-time fees. The company, based in Laval near Montreal, said early Thursday that it had received lender approvals that give Valeant more flexibility to borrow money and sell assets - part of the company's plan to reduce its debt load.



from Biotech News